Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899099 | 0.96 | MEN1 (0.34) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL17899089 | 0.91 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL17899093 | 0.90 | MEN1 (0.31) | MEN1ALDH1A1KMT2AATM | |
| SCHEMBL17827735 | 0.88 | ALDH1A1 (0.37) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL12932552 | 0.87 | ALDH1A1 (0.38) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL17902873 | 0.86 | MEN1 (0.31) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL18031811 | 0.85 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL17899100 | 0.85 | ALDH1A1 (0.42) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL17828628 | 0.82 | ALDH1A1 (0.37) | MEN1ALDH1A1KMT2AATMCYP17A1 | |
| SCHEMBL17902871 | 0.82 | PKM (0.31) | MEN1ALDH1A1KMT2AATMCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9575408-B2 | Photoresist composition and method for producing photoresist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160195809-A1 | PHOTORESIST COMPOSITION AND METHOD FOR PRODUCING PHOTORESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160195809-A1 | PHOTORESIST COMPOSITION AND METHOD FOR PRODUCING PHOTORESIST PATTERN | RER1, LCP1, COL1A1 | MEN1 1607/4885ALDH1A1 914/4885KMT2A 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.